Robust Delivery of RIG-I Agonists Using Extracellular Vesicles for Anti-cancer Immunotherapy

The authors demonstrated the use of extracellular vesicles from red blood cells, which were highly amenable for RNA loading and taken up robustly by cancer cells, for RIG-I agonist delivery.